1. Home
  2. GOF vs EVO Comparison

GOF vs EVO Comparison

Compare GOF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guggenheim Strategic Opportunities Fund of Beneficial Interest

GOF

Guggenheim Strategic Opportunities Fund of Beneficial Interest

HOLD

Current Price

$10.60

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.43

Market Cap

895.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOF
EVO
Founded
N/A
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
895.8M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
GOF
EVO
Price
$10.60
$2.43
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
1.6M
108.8K
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.74
$2.31
52 Week High
$15.69
$4.80

Technical Indicators

Market Signals
Indicator
GOF
EVO
Relative Strength Index (RSI) 22.60 34.47
Support Level N/A $2.31
Resistance Level $15.10 $3.78
Average True Range (ATR) 0.17 0.08
MACD -0.02 0.01
Stochastic Oscillator 1.69 25.54

Price Performance

Historical Comparison
GOF
EVO

About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest

Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: